Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Research & Drug Development

2003

A. Thomas; C. Cattaneo; C. Besana; P. Sala; M. Onofrj; M. Baratti; G. Nordera; T. Mesiano; G. Fabbrini; P. Barbanti; R. Fariello
Funzionalità motoria: follow-up su pazienti parkinsoniani in precedenza trattati con safinamide
XXX Congresso Nazionale LIMPE Pescara, 19/21 Novembre - 2003

M. Onofrj; C. Cattaneo; F. Stocchi; L. Vacca; A.Thomas; R. Fariello
Safinamide migliora la funzionalità motoria in pazienti parkinsoniani
XXX Congresso Nazionale LIMPE Pescara, 19/21 Novembre - 2003

C.T. Chung; P. Guidetti; E. Izzo; F.J.Denaro; O. Jones; J.L. Bryant; R. Schwarcz
Slowly evolving increase in brain quinolinic acid levels in a HIV-1 transgenic rat
33rd Annual meeting Society for Neuroscience New Orleans, November 8-12 - 2003

M. Woltz; M. Muller; C. Leuratti; C. Cattaneo; R. Fariello
First dose in man of ralfinamide, a new CNS drug with central analgesic effect
XXXIV Congresso Società Italiana di Neurologia - SIN Roma, 11-15 October 2003

T. Stummann; P. Salvati; R. Fariello; L. Faravelli
NW-1029, an alpha-aminoamide derivative with antihuperalgesic and antiallodynic properties inhibits NA+ currents in rat sensory neurons
4th Congress of EFIC - Prague, Czech Republic, September 2-6, 2003

Salvati P.; Faravelli L.; Veneroni O.
TTX-sensitive and TTX-resistant sodium channels
226th ACS National Meeting New York, 7-11 September 2003

Girola L.; Salvati P.; Caccia C.
Amyloid Beta1-42 spontaneous aggregation: a suitable "slow" process to detect compounds interfering with amyloid fibril formation
SINS 2003, Pisa, 26-28 September

Restivo A.; Maestroni S.; Fariello R.G.; Salvati P.; Caccia C.
Involvement of mitogen-activated protein kinases in oxidative stress-induced cell death in human SH-SY5Y neuroblastoma cells
SINS 2003, Pisa, 26-28 September

Curatolo L.; Izzo E.; Caccia C.; Dho L.; Lamberti E.; Parini S.; Salvati P.
Role of Kynurenine pathway in an in vitro model of cataract
SINS, 2003-Pisa, 26-28 September

Izzo E.; Carpened R.; Cozzi A.; Cipriani G.; Veneroni O.; Moroni F.
Effects of Kynurenine 3-mono-oxygenase Inhibitors on Learning and Memory and Glutamate Release in Different Rat Brain Areas.
Neuroscience New Orleans, USA 8-12 November, 2003

Curatolo L.; Faravelli L.; Caccia C.; Salvati P.
Ion Channel as a Therapeutic Target for Neuroprotection:safinamide.
Neurotox 2003 Nottingham, UK UK 1-4 September

Faravelli L.; Fariello R.G.; Salvati P.;
Inhibition of TTXr Na+currents in Rat Sensory Neurons by NW-1029, a New Antihyperalgesic Agent.
Proceeding of the 10th Congress on Pain, Progress in Pain Research and Management ( 2003) Vol. 24:115-124

Veneroni O.; Maj R.; Calabresi M.; Faravelli L.; Fariello R.G.; Salvati P.
Antiallodynic Effect of NW-1029, a Novel Na+Chanel Blocker In Experimental Animal Models of Inflammatory and Neuropathic Pain.
Pain 102, 17-25, 2003